Bilateral Stellate Ganglion Blockade for Recalcitrant Oral Pain from Burning Mouth Syndrome: A Case Report

Burning Mouth Syndrome (BMS) is a chronic painful disorder characterized by unremitting bilateral burning oral pain often associated with taste abnormalities and complaints of dry mouth. The diagnosis is made by history and symptom presentation in the absence of an identifiable cause or oral lesion. It is commonly seen in perimenopausal women but is also seen in men, and is considered a small-fiber neuropathy. Management can be challenging and few effective treatments are available. This article presents a case report of stellate ganglion blockade as a treatment for recalcitrant pain from BMS.

burning mouth syndrome; neuropathic pain stellate ganglion injection; small-fiber neuropathy; trigeminal nerve

1. Danhauer SC, Miller CS, Rhodus NL, Carlson CR. Impact of criteria-based diagnosis of burning mouth syndrome on treatment outcome. J Orofac Pain 2002;16:305–311.

2. Woda A, Navez ML, Picard P, Gremeau C, Pichard-Leandri E. A possible therapeutic solution for stomatodynia (burning mouth syndrome). J Orofac Pain 1998;12:272–278.

3. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002;65:615–620.

4. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome and other oral sensory disorders: A unifying hypothesis. Pain Res Manag 2003;8:133–135.

5. Merskey H, Bogduk N. International Association for the Study of Pain. Task Force on Taxonomy. Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. Seattle: IASP Press, 1994:xvi.

6. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc 1993;124:115–121.

7. Bergdahl M, Bergdahl J. Burning mouth syndrome: Prevalence and associated factors. J Oral Pathol Med 1999;28:350–354.

8. Cairns BE. The influence of gender and sex steroids on cranio-facial nociception. Headache 2007;47:319–324.

9. Lauria G, Majorana A, Borgna M, et al. Trigeminal smallfiber sensory neuropathy causes burning mouth syndrome. Pain 2005;115:332–337.

10. Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007;14:864–871.

11. Nagler RM, Hershkovich O. Sialochemical and gustatory analysis in patients with oral sensory complaints. J Pain 2004;5: 56–63.

12. Tammiala-Salonen T, Soderling E. Protein composition, adhesion, and agglutination properties of saliva in burning mouth syndrome. Scand J Dent Res 1993;101:215–218.

13. Grushka M, Sessle BJ, Miller R. Pain and personality profiles in burning mouth syndrome. Pain 1987;28:155–167.

14. Granot M, Nagler RM. Association between regional idiopathic neuropathy and salivary involvement as the possible mecha-nism for oral sensory complaints. J Pain 2005;6:581–587.

15. Forssell H, Jaaskelainen S, Tenovuo O, Hinkka S. Sensory dys-function in burning mouth syndrome. Pain 2002;99:41–47.

16. Koszewicz M, Mendak M, Konopka T, Koziorowska-Gawron E, Budrewicz S. The characteristics of autonomic nervous system disorders in burning mouth syndrome and Parkinson disease. J Orofac Pain 2012;26:315–320.

17. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003;101:149–154.

18. Albuquerque RJ, de Leeuw R, Carlson CR, Okeson JP, Miller CS, Andersen AH. Cerebral activation during thermal stimulation of patients who have burning mouth disorder: An fMRI study. Pain 2006;122:223–234.

19. Souza FT, Santos TP, Bernardes VF, et al. The impact of burn-ing mouth syndrome on health-related quality of life. Health Qual Life Outcomes 2011;9:57.

20. Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carrassi A. Burning mouth syndrome: A retrospective study investigating spontaneous remission and response to treatments. Oral Dis 2006;12:152–155.

21. de Moraes M, do Amaral Bezerra BA, da Rocha Neto PC, de Oliveira Soares AC, Pinto LP, de Lisboa Lopes Costa A. Randomized trials for the treatment of burning mouth syndrome: An evidence-based review of the literature. J Oral Pathol Med 2012;41:281–287.

22. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonaz-epam in stomatodynia: A randomised placebo-controlled study. Pain 2004;108:51–57.

23. Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope 2012;122:813–816.

24. Rodriguez-Cerdeira C, Sanchez-Blanco E. Treatment of burning mouth syndrome with amisulpride. J Clin Med Res 2012; 4:167–171.

25. Toida M, Kato K, Makita H, et al. Palliative effect of lafutidine on oral burning sensation. J Oral Pathol Med 2009;38:262–268.

26. Nagashima W, Kimura H, Ito M, et al. Effectiveness of duloxe-tine for the treatment of chronic nonorganic orofacial pain. Clin Neuropharmacol 2012;35:273–277.

27. Pezelj-Ribaric S, Kqiku L, Brumini G, et al. Proinflammatory cytokine levels in saliva in patients with burning mouth syndrome before and after treatment with low-level laser therapy. Lasers Med Sci 2013;28:297–301.

28. dos Santos Lde F, Carvalho Ade A, Leao JC, Cruz Perez DE, Castro JF. Effect of low-level laser therapy in the treatment of burning mouth syndrome: A case series. Photomed Laser Surg 2011;29:793–796.

29. White TL, Kent PF, Kurtz DB, Emko P. Effectiveness of gabapentin for treatment of burning mouth syndrome. Arch Otolaryngol Head Neck Surg 2004;130:786–788.

30. Lopez V, Alonso V, Marti N, Calduch L, Jorda E. Marked response of burning mouth syndrome to pregabalin treatment. Clin Exp Dermatol 2009;34:e449–e450.

31. Siniscalchi A, Gallelli L, Marigliano NM, Orlando P, De Sarro G. Use of topiramate for glossodynia. Pain Med 2007;8:531–534.

32. Stuginski-Barbosa J, Rodrigues GG, Bigal ME, Speciali JG. Burning mouth syndrome responsive to pramipexol. J Headache Pain 2008;9:43–45.

33. Bergdahl J, Anneroth G, Perris H. Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: a controlled study. J Oral Pathol Med 1995;24:213–215.

34. Elias M. Cervical sympathetic and stellate ganglion blocks. Pain Physician 2000;3:294-304.

35. Salvaggio I, Adducci E, Dell’Aquila L, et al. Facial pain: A possible therapy with stellate ganglion block. Pain Med 2008;9: 958–962.

36. Benedetti F, Amanzio M. The neurobiology of placebo analgesia: From endogenous opioids to cholecystokinin. Prog Neurobiol 1997;52:109–125.

37. Wang QX, Wang XY, Fu NA, Liu JY, Yao SL. Stellate ganglion block inhibits formalin-induced nociceptive responses: Mechanism of action. Eur J Anaesthesiol 2005;22:913–918.

38. Herzberg U, Eliav E, Dorsey JM, Gracely RH, Kopin IJ. NGF involvement in pain induced by chronic constriction injury of the rat sciatic nerve. Neuroreport 1997;8:1613–1618.

39. Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 2008;437:199–202.

40. Lipov EG, Joshi JR, Sanders S, Slavin KV. A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Med Hypotheses 2009;72:657–661.

41. Westerhaus MJ, Loewy AD. Central representation of the sympathetic nervous system in the cerebral cortex. Brain Res 2001;903:117–127.

42. Gremeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, Woda A. Effect of lingual nerve block on burning mouth syndrome (stomatodynia): a randomized crossover trial. Pain 2010;149:27–32.

43. Wulf H, Maier C. Complications and side effects of stellate ganglion blockade. Results of a questionnaire survey [in German]. Anaesthesist 1992;41:146–151.